Weight Loss Drug Injury Attorneys Louisiana
Mainstream and social media coverage have created a surge in the usage of injectable type 2 diabetes medications, such as Ozempic® and Rybelsus®, for weight loss purposes.
While these glucagon-like peptide-1 (GLP-1) agonists were designed to help type 2 diabetes patients regulate their blood sugar levels, they have recently emerged as effective tools for weight reduction. This unforeseen benefit has led medical practitioners to prescribe them off-label for weight loss, alongside another GLP-1 agonist named Wegovy®, which is designed and prescribed exclusively for weight loss.
GLP-1 Agonists Are Linked to Serious Complications
Recent reports and litigation involving GLP-1 agonists have focused on serious vision-related injuries, including non-arteritic anterior ischemic optic neuropathy (NAION), sometimes referred to in the media as “Ozempic blindness.” NAION is a condition caused by reduced blood flow to the optic nerve and may lead to sudden, permanent vision loss.
In addition to reported vision injuries, GLP-1 agonists have also been associated with severe gastrointestinal complications in some patients, including medically documented gastroparesis (stomach paralysis).
Reported complications linked to GLP-1 agonists include:
- Vision loss
- NAION (non-arteritic anterior ischemic optic neuropathy)
- Blindness or partial blindness
- Gastroparesis (stomach paralysis) diagnosed through objective medical testing
- Severe gastrointestinal injury requiring hospitalization
- Pancreatitis requiring hospitalization
- Acute kidney injury or kidney failure
- Gallbladder disease or gallstones requiring treatment or surgery
If you or a loved one used a GLP-1 agonist like Ozempic®, Wegovy®, or Rybelsus® and subsequently suffered vision loss, NAION, blindness, or another serious medically documented complication, our legal team wants to speak with you. We are reviewing claims involving severe injuries allegedly linked to GLP-1 agonists and helping qualifying individuals pursue compensation for medical expenses, lost income, and pain and suffering.
What Is the Link Between GLP-1 Agonists and Vision Loss?
Studies and adverse event reports have raised concerns about a potential association between GLP-1 agonists and NAION, a serious eye condition involving reduced blood flow to the optic nerve. NAION may develop suddenly and can cause permanent vision impairment or blindness in one or both eyes.
Patients who experience sudden vision changes, blurred vision, or unexplained vision loss after using GLP-1 medications should seek immediate medical attention.
What Is the Link Between GLP-1 Agonists and Digestive System Problems?
GLP-1 agonists contribute to weight loss by slowing the rate at which the stomach empties. Because food stays in the stomach longer, people taking these medications may feel full for longer periods, leading to reduced caloric intake and eventual weight loss. However, delayed stomach emptying may also contribute to severe gastrointestinal complications in certain individuals.
Some patients have reported persistent gastrointestinal symptoms and, in more serious cases, medically confirmed gastroparesis (stomach paralysis). Gastroparesis is a condition that can interfere with normal digestion and may lead to malnutrition, dehydration, gastroesophageal reflux disease (GERD), and other serious complications.
Potential gastroparesis claims generally require objective medical evidence, such as diagnostic testing or a documented diagnosis from a treating physician.
What Is the Link Between GLP-1 Agonists and Organ Damage?
The precise mechanisms underlying how GLP-1 agonists may contribute to organ damage and other severe injuries remain under investigation. However, reports and studies have suggested potential links between these medications and several serious complications in some individuals:
- GLP-1 agonists have been associated with an increased risk of pancreatitis.
- Some patients have reported kidney impairment requiring medical intervention or dialysis.
- Animal studies have identified a potential link between GLP-1 agonists and thyroid C-cell tumors.
- GLP-1 agonists may place stress on the gallbladder, contributing to gallstones and related complications that can require surgery.
Reach Out Today to Get an Experienced Drug Injury Lawyer on Your Side
The complications associated with GLP-1 agonists, including Ozempic®, Rybelsus®, and Wegovy®, may be severe and life-changing for some patients, particularly in cases involving permanent vision loss or medically documented gastrointestinal injury.
We believe patients deserve clear information about the potential risks associated with these medications. Individuals who allegedly suffered serious injuries after using GLP-1 agonists may have legal options available to them.
Contact our legal team today for a free case review to learn whether you may qualify to pursue compensation.
